实用药物与临床
實用藥物與臨床
실용약물여림상
Practical Pharmacy and Clinical Remedies
2015年
10期
1174-1176
,共3页
西妥昔单抗%晚期头颈部鳞癌%成本-效果分析
西妥昔單抗%晚期頭頸部鱗癌%成本-效果分析
서타석단항%만기두경부린암%성본-효과분석
Cetuximab%Advanced head and neck squamous cell cancer%Cost-effectiveness analysis
目的 研究西妥昔单抗联合化疗用于晚期头颈部鳞癌患者的成本效果性.方法 根据 EX-TREME临床试验数据,结合我国医疗费用及消费水平,进行成本-效果分析,并对结果进行敏感度分析.结果 西妥昔单抗联合化疗方案相较于单纯化疗方案,每例患者总生存期增加1 个月,需多花费50 327.0 元人民币.结论 西妥昔单抗联合化疗方案相对于单纯化疗方案不具有成本效果优势.
目的 研究西妥昔單抗聯閤化療用于晚期頭頸部鱗癌患者的成本效果性.方法 根據 EX-TREME臨床試驗數據,結閤我國醫療費用及消費水平,進行成本-效果分析,併對結果進行敏感度分析.結果 西妥昔單抗聯閤化療方案相較于單純化療方案,每例患者總生存期增加1 箇月,需多花費50 327.0 元人民幣.結論 西妥昔單抗聯閤化療方案相對于單純化療方案不具有成本效果優勢.
목적 연구서타석단항연합화료용우만기두경부린암환자적성본효과성.방법 근거 EX-TREME림상시험수거,결합아국의료비용급소비수평,진행성본-효과분석,병대결과진행민감도분석.결과 서타석단항연합화료방안상교우단순화료방안,매례환자총생존기증가1 개월,수다화비50 327.0 원인민폐.결론 서타석단항연합화료방안상대우단순화료방안불구유성본효과우세.
Objective To compare the cost-effectiveness of cetuximab in combination with chemotherapy ver-sus chemotherapy alone for advanced head and neck squamous cell cancer. Methods According to EXTREME clinical trial data,cost-effectiveness and sensitivity analysis of the results was conducted based on domestic costs and consump-tion levels. Results Cetuximab in combination with chemotherapy regimen could prolong one month of overall surviv-al with additional cost of 50 327.0 yuan in each case compared to chemotherapy alone regimen. Conclusion Cetux-imab in combination with chemotherapy does not suggest better cost effectiveness compared to chemotherapy alone.
